Thymic carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:16 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Thymic carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-domvanalimab-and-zimberelimab-for-adults-with-advanced-rare-cancers-resistant-to-standard-treatment/ Wed, 29 Apr 2026 15:05:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-domvanalimab-and-zimberelimab-for-adults-with-advanced-rare-cancers-resistant-to-standard-treatment/ This clinical trial is focused on studying the effects of a new treatment combination for patients with advanced forms of five rare cancers. These cancers include peritoneal mesotheliomas, gestational trophoblastic tumors, B3 thymomas and thymic carcinomas, anaplastic thyroid carcinomas, and gastroenteropancreatic neuroendocrine tumors (GEP-NET) and carcinoid tumors. The treatment being tested is a combination of two medications: Domvanalimab and Zimberelimab. Domvanalimab is also known by its code name AB154, and Zimberelimab is referred to as AB122. These medications are designed to work together to help the immune system fight cancer more effectively.

The purpose of the study is to evaluate how well this combination treatment works in patients whose cancers have progressed or become resistant after at least one standard treatment. The study will involve patients receiving the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 24 weeks, during which the effectiveness and safety of the treatment will be closely monitored. Patients will be grouped into different cohorts based on their specific type of cancer, and the study will assess various outcomes, such as the rate of cancer progression and overall survival.

Throughout the study, researchers will collect data to understand how the treatment affects the different types of rare cancers. The goal is to determine if the combination of Domvanalimab and Zimberelimab can provide a new and effective treatment option for patients with these challenging conditions. The study is part of a larger effort to explore innovative therapies for rare cancers, which often have limited treatment options. By participating in this trial, researchers hope to gather valuable information that could lead to improved care for patients with these rare and advanced cancers.

]]> Study on Pembrolizumab and Lenvatinib for Patients with Pre-Treated Thymic Carcinoma and B3-Thymoma https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-lenvatinib-for-patients-with-pre-treated-thymic-carcinoma-and-b3-thymoma/ Wed, 29 Apr 2026 14:25:31 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-lenvatinib-for-patients-with-pre-treated-thymic-carcinoma-and-b3-thymoma/ This clinical trial is focused on studying the effectiveness and safety of a combination treatment for patients with a type of cancer called thymic carcinoma and a subtype known as B3-thymoma. These are rare cancers that occur in the thymus, a small organ in the upper chest. The treatment being tested includes two medications: pembrolizumab, also known by its code name MK-3475, and lenvatinib, known by its code name MK-7902. Pembrolizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein, while lenvatinib is taken orally in capsule form.

The purpose of this study is to evaluate how well this combination of medications works in patients who have already received other treatments for their cancer. The study will look at how long patients can live without their disease getting worse over a period of five months. Participants will receive the treatment for up to 24 months, and their health will be monitored regularly to assess the treatment’s effects and any side effects they may experience.

Throughout the study, researchers will also gather information on how the cancer responds to the treatment, including any reduction in tumor size and overall survival rates. The safety of the treatment will be closely monitored to ensure it is well-tolerated by patients. This study aims to provide valuable insights into the potential benefits of using pembrolizumab and lenvatinib together for treating thymic carcinoma and B3-thymoma.

]]>